The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease.
Paul G RichardsonMaria-Victoria Mateos-MantecaAnnette J VangstedKarthik RamasamyNiels AbildgaardP Joy HoHang QuachNizar J BahlisPublished in: Expert review of proteomics (2022)
Since a high proportion of patients develop drug resistance, it is vital to have novel therapeutic agents for treating relapsed patients with MM more effectively. It is encouraging that the expanding pathophysiological insight into cellular signaling pathways in MM increasingly translates into the development of novel therapeutic agents such as targeted protein degraders. This holds promise for improving outcomes in MM and beyond.
Keyphrases
- multiple myeloma
- acute lymphoblastic leukemia
- end stage renal disease
- acute myeloid leukemia
- diffuse large b cell lymphoma
- ejection fraction
- signaling pathway
- hodgkin lymphoma
- newly diagnosed
- chronic kidney disease
- small molecule
- prognostic factors
- big data
- adipose tissue
- climate change
- artificial intelligence
- amino acid
- endoplasmic reticulum stress